Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 28 for:    Behaviors and Mental Disorders[CONDITION-BROWSE-BRANCH] | Recruiting, Not yet recruiting, Available Studies | ( Map: Utah, United States ) | NIH, U.S. Fed

Addiction Treatment in Primary Care Expansion (APEX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03547882
Recruitment Status : Recruiting
First Posted : June 6, 2018
Last Update Posted : April 18, 2019
Sponsor:
Collaborators:
VA Eastern Colorado Health Care System
University of Colorado, Denver
University of Utah
Information provided by (Responsible Party):
VA Office of Research and Development

Brief Summary:

The Veterans Health Administration (VA) is a national leader in addressing the twin epidemics of chronic pain and opioid use, misuse, and opioid use disorder (OUD); but important challenges remain. Both chronic pain and OUD are more common among Veterans compared to the general population.1 As the VA transitions toward a greater emphasis on non-opioid chronic pain treatments, improving access to OUD treatment will be critical for those Veterans with new diagnoses of OUD in the context of long-term opioid therapy. Strong evidence supports the treatment of OUD with medications, including naltrexone, buprenorphine, and methadone.2 Buprenorphine and naltrexone can be prescribed in primary care settings; OUD treatment in primary care is associated with decreased opioid use, higher quality of care, and improved quality of life.3-5 In partnership with VISN19 leadership, this project will address the priority goal of improving access to medication-assisted therapy for OUD treatment. The objective of the VISN Partnered Implementation Initiative startup phase (PHASE 1) is to implement and evaluate the evidence-based, effective practice of medication treatment of opioid use disorder in primary care settings. A subsequent PHASE 2 will study the implementation of strategies from PHASE 1 across the entire VISN19. The investigators propose two specific aims:

Aim 1: Evaluate the implementation and impact of a multifaceted provider support initiative at two VA medical centers and four community-based clinics in VISN19 using the integrated-Promoting Action on Research Implementation in Health Services (i-PARIHS) implementation framework. The multifaceted initiative will leverage existing VA and VISN resources (including e-consults, telementoring and telehealth) to facilitate improved access to OUD treatment in primary care.

Aim 2: Create an interactive implementation toolkit with guidance on facilitation and incentive strategies and resources for broader dissemination across the VISN and VA.


Condition or disease
Opioid Use Disorder (OUD) Chronic Pain

Detailed Description:

Among Veterans receiving healthcare from the Veterans Health Administration (VA), there has been sharp rise in the number of veterans diagnosed with opioid use disorder (OUD). In 2013, 25,031 Veterans had OUD and in 2017, Veterans with OUD nearly tripled to 69,142.6 As the largest direct provider of addiction treatment nationally, VA has taken steps to increase access to medication treatment for OUD, which is recognized as an essential component of evidence-based care.

The treatment of OUD involves several FDA-approved, VA formulary medications including naltrexone, methadone, and buprenorphine/naloxone and buprenorphine (hereafter collectively termed buprenorphine). Strong evidence supports the treatment of OUD with medications, and they are the "gold standard" treatments for OUD. Medications for OUD have been shown to substantially decrease risk for all-cause mortality and overdose mortality in people with opioid use disorder. Unlike methadone, buprenorphine for OUD can be prescribed in office-based settings such as primary care, and buprenorphine delivered in primary care is associated with decreased opioid use, higher quality of care, and improved quality of life. Medication treatment includes dispensation of methadone and buprenorphine in licensed opioid treatment programs (OTPs) and prescriptions of buprenorphine and naltrexone in office-based settings. Because there are only 32 licensed OTPs in the VA, buprenorphine and naltrexone prescriptions are the means to improve access to medication treatment for Veterans with OUD. Uptake of medication treatment, however, has been slow and uneven in the VA. In 2017, 35% of Veterans diagnosed with OUD had received OUD medications.

In VISN19, rates of OUD and OUD treatment are low and heterogeneous across facilities and compared with the national average (35%), fewer patients with OUD are on OUD medications (21%) in VISN19. Multiple initiatives have been instituted to improve access to medication treatment for Veterans with OUD, particularly in non-specialty office-based settings. In 2007, VA introduced the Buprenorphine in the VA Initiative (BIV; Director Gordon), a national consult service, which aimed to improve care processes and patient outcomes associated with buprenorphine. In 2010, VA unrolled Academic Detailing program in which pharmacy specialists take on high-priority pharmaceutical education campaigns. An Academic Detailing campaign specifically targeting the treatment of opioid use disorder was initiated in 2017. Further improving access to evidence-based medication treatment of OUD remains a priority for VA and VISN19.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Other
Time Perspective: Other
Official Title: APEX- Addiction Treatment in Primary Care Expansion (PII 18-181)
Actual Study Start Date : May 1, 2018
Estimated Primary Completion Date : September 30, 2019
Estimated Study Completion Date : September 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Chronic Pain

Group/Cohort
Other
Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
Patients
Ten interviews were conducted with VA patients receiving ORT.



Primary Outcome Measures :
  1. Number of patients who receive mediation assisted treatment for opioid use disorder (by facility and community based clinic) [ Time Frame: 12 Months ]
    Electronic health record and Administrative data will be pulled to assess outcomes

  2. Ratio of patients receiving medication assisted treatment for opioid use disorder to the number of patients with opioid use disorder (by facility and community based clinic) [ Time Frame: 12 Months ]
    Electronic health record and Administrative data will be pulled to assess outcomes

  3. Change in number of providers prescribing medication assisted treatment for opioid use disorder and patients receiving medication assisted treatment (by facility) [ Time Frame: baseline through 1 year ]
    Interviews to stakeholders facilitated by field note review will be conducted to examine facilitators and barriers of implementation

  4. Patients receiving medication assisted treatment (by facility) [ Time Frame: 12 Months ]

    The investigators will be using the VA Academic Detailing Data Tool System which includes different measures with real time patient tracker to identify patients receiving medication assisted treatment.

    By using different dashboards the investigators will be pulling number of patients with buprenorphine treatment and the number of OUD patients with OUD pharmacotherapy from this dashboards.



Biospecimen Retention:   None Retained
No Bio specimen collection


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
VA Medical Providers and VA patients receiving ORT
Criteria

Inclusion Criteria:

  • Inclusion criteria include health care providers at 2 main VA facilities and four VA community based outpatient clinics
  • VA patients receiving ORT

Exclusion Criteria:

  • N/A

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03547882


Contacts
Layout table for location contacts
Contact: Adam J Gordon, MD MPH (801) 582-1565 ext 4169 adam.gordon@va.gov
Contact: Nodira Codell, MPA (801) 582-1565 nodira.codell@va.gov

Locations
Layout table for location information
United States, Colorado
VA Eastern Colorado Health Care System, Denver, CO Enrolling by invitation
Denver, Colorado, United States, 80220
United States, Utah
VA Salt Lake City Health Care System, Salt Lake City, UT Recruiting
Salt Lake City, Utah, United States, 84148
Contact: Misti R Seppi, MBA BS AAS    801-582-1565 ext 4860    Misti.Seppi@va.gov   
Contact: Amyanne Wuthrich, MS BS    (801) 582-1565 ext 2419    Amyanne.Wuthrich@va.gov   
Principal Investigator: Adam J. Gordon, MD MPH         
Sponsors and Collaborators
VA Office of Research and Development
VA Eastern Colorado Health Care System
University of Colorado, Denver
University of Utah
Investigators
Layout table for investigator information
Principal Investigator: Adam J. Gordon, MD MPH VA Salt Lake City Health Care System, Salt Lake City, UT
Principal Investigator: Joseph W Frank, MD MPH Rocky Mountain Regional VA Medical Center, Aurora, CO

Layout table for additonal information
Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT03547882     History of Changes
Other Study ID Numbers: PIX 18-002
PII 18-181 ( Other Grant/Funding Number: Quality Enhancement Research Initiative (QUERI) )
First Posted: June 6, 2018    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by VA Office of Research and Development:
Opioid
Buprenorphine
Naltrexone
methadone

Additional relevant MeSH terms:
Layout table for MeSH terms
Chronic Pain
Pain
Neurologic Manifestations
Signs and Symptoms